Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease
Guoyan Xu(Children's Hospital of Philadelphia), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Jürgen Venitz(National Cancer Institute), Qiukan Chen(Children's Hospital of Philadelphia), Ronni P. Safo(Children's Hospital of Philadelphia), Alhumaidi B. Alabbas(Children's Hospital of Philadelphia), Mohini S. Ghatge(Children's Hospital of Philadelphia), Piyusha P. Pagare(Virginia Commonwealth University), Yan Zhang(Virginia Commonwealth University), Tanya David(Children's Hospital of Philadelphia), Faik N. Musayev(Virginia Commonwealth University), Aheema Gazi(University of Richmond), Martin K. Safo(Virginia Commonwealth University)
Cited by 55
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
2‐Methoxyestradiol, a Promising Anticancer Agent
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2003|276
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
G Protein–Coupled Receptor Deorphanizations
|The Annual Review of Pharmacology and Toxicology|2011|193